Finvest
TRVI Biotechnology · Clinical stage · Single asset · Chronic cough · Thesis updated July 12, 2026

Funded into 2030, still one drug

01 Running thesis

A cleaner Phase 3 bet

Trevi is now a late-stage clinical trial story. In March 2026, management said it had a positive End-of-Phase 2 meeting with the FDA for Haduvio in IPF-related chronic cough. That matters because it gave the company a clearer path for two pivotal Phase 3 trials, the kind of trials meant to support an FDA approval filing.

The April 2026 financing changed the money side of the thesis. Trevi sold 11,600,000 shares at $13.00 per share and raised about $162 million in net proceeds. Management now says cash, cash equivalents, and marketable securities can fund operations into 2030, including the two planned IPF Phase 3 trials potentially through FDA approval.

That strengthens the bull case. Investors no longer have to assume Trevi will need another large stock sale just to finish the core IPF program. The company can focus on enrolling patients, running the trials, and preparing for a possible launch.

The bear case is still serious. Trevi depends on one drug candidate. If Haduvio fails in the Phase 3 IPF trials, the company would lose its main value driver, even though it has enough cash to keep working for several years.

May 2026▲Trevi disclosed an April 2026 stock offering with about $162 million in net proceeds. Management now says cash runway extends into 2030, which lowers funding risk for the IPF Phase 3 program.
Mar 2026▲Trevi said it had a positive End-of-Phase 2 meeting with the FDA for Haduvio in IPF-related chronic cough. The update shifted the story toward Phase 3 execution.
Nov 2025▲Supportive Phase 1 safety and drug interaction updates reduced some open clinical questions. Cash runway into 2028 was also reaffirmed at that time.
Aug 2025▲Trevi reported positive full Phase 2b CORAL data and raised about $115 million in capital. The update strengthened the clinical case and reduced near-term financing pressure.
May 2025→The initial public page view framed Trevi as a single-asset clinical-stage biotech. The main setup was the pending Phase 2b CORAL readout and the risk of depending on Haduvio.
02 Business model

No sales yet, one future product

Trevi does not make money from product sales today. It is spending investor capital to test Haduvio in several types of chronic cough. The business only works if Haduvio wins approval, doctors prescribe it, and payers agree to cover it.

Haduvio is oral nalbuphine ER, meaning an extended-release pill form of nalbuphine. Trevi believes its central and peripheral action could help calm abnormal cough signaling. That is the main scientific reason for the company to exist.

The model is high risk but easy to understand. Clinical data create value, failed trials destroy value, and future profits would require Trevi to build or partner a commercial sales effort. The April 2026 raise lowers near-term funding risk, but it does not lower the chance that biology disappoints.

03 Product portfolio

One drug, several shots

Growth engine

Haduvio for IPF chronic cough

This is the lead program. Trevi plans two pivotal Phase 3 trials after FDA feedback, with the first starting in Q2 2026 and the second in H2 2026.

Growth engine

Haduvio first IPF Phase 3 trial

The first IPF trial is planned as a 52-week study with the main efficacy check at 24 weeks. This trial is the first major test of whether Phase 2 cough results can hold up in a larger study.

Growth engine

Haduvio second IPF Phase 3 trial

The second IPF trial is the confirmatory study, with a main efficacy check at 12 weeks. Success in both trials would be central to a possible FDA approval package.

Option

Haduvio for refractory chronic cough

Trevi plans a Phase 2b dose-ranging study in refractory chronic cough, or RCC, in Q2 2026. This could widen Haduvio beyond lung scarring diseases if the dose and benefit are clear.

Option

Haduvio for non-IPF ILD chronic cough

Trevi plans to ask the FDA in Q3 2026 about an adaptive Phase 2b trial in non-IPF interstitial lung disease, or non-IPF ILD. The key question is whether regulators accept the proposed trial design.

04 Business segments

A single development company

Haduvio development100%growing fast
Commercial product revenue0%flat

Trevi reports as a clinical-stage company with no commercial products and no geographic revenue mix. For this page, the mix reflects the March 31, 2026 filing context: essentially all economic exposure is Haduvio development, while commercial product revenue is zero.

05 Risk factors

What could break

Phase 3 IPF failure

High impact · Medium odds

The main value driver is Haduvio in IPF-related chronic cough. Phase 2 results helped the case, and FDA feedback clarified the path, but larger pivotal trials can still fail. If the primary cough endpoints miss, Trevi would have few other ways to support its valuation.

We watchTop-line data from the two IPF Phase 3 trials, especially the 24-week endpoint in the first trial and the 12-week endpoint in the confirmatory trial.

Slow trial enrollment

High impact · Medium odds

Trevi must enroll patients with serious lung disease who also have chronic cough. If enrollment is slower than planned, data readouts and any approval filing could move out. A delay would not mean failure, but it would burn cash and test investor patience.

We watchCompany updates on first patient dosed, site activation, enrollment pace, and any changes to Phase 3 timeline guidance.

Single-product dependence

High impact · High odds

Trevi has one drug candidate, Haduvio. The company is testing it in several cough settings, but those programs still depend on the same molecule. A safety, efficacy, or regulatory problem with Haduvio would hit the whole company.

We watchSafety updates, dropout rates, dose changes, and any FDA requests for extra studies tied to Haduvio.

Non-IPF ILD design risk

Medium impact · Medium odds

Trevi wants to discuss an adaptive Phase 2b trial for chronic cough in non-IPF ILD. Adaptive means the trial may change certain features based on planned interim looks. The open question is whether the FDA agrees with the design and what evidence it will require.

We watchFDA meeting feedback expected in Q3 2026 and management comments on whether a year-end trial start remains possible.

Launch buildout risk

Medium impact · Medium odds

Even if Haduvio is approved, Trevi still has to sell it. That means hiring sales staff, educating doctors, supporting reimbursement, and possibly raising more capital for launch. A good drug can still disappoint commercially if access or adoption is weak.

We watchEarly hiring plans, payer strategy, partnership talk, and launch spending guidance as Phase 3 data gets closer.
06 Quick answers

In one breath

Does Trevi Therapeutics have any approved drugs?

No. Trevi is a clinical-stage biotech, so it does not have approved products or commercial product revenue today. Its only drug candidate is Haduvio.

What is Haduvio being tested for?

Haduvio is being tested for chronic cough in IPF, refractory chronic cough, and chronic cough in non-IPF ILD. The lead program is IPF-related chronic cough, where Trevi is moving into two Phase 3 trials.

Why did the April 2026 financing matter?

Trevi raised about $162 million in net proceeds from a public stock offering. Management says this extends cash runway into 2030 and can fund the IPF Phase 3 program potentially through FDA approval.

What is the biggest near-term thing to watch?

The key watch item is execution of the IPF Phase 3 program. Investors should track trial starts, enrollment pace, and later the top-line cough endpoint results.